Anuh Pharma (506260) Q2 26/27 earnings summary

Executive summary

• H1 FY27 revenue was ₹37,905.18 lakh, up 1.80% YoY; PAT rose 42.25% to ₹2,263.80 lakh, with higher-value mix supporting profitability.

• Production increased 15.31% YoY to 987 MT; H2 priorities include rebuilding exports and pursuing 15–20% annual growth.

• Unaudited results for the quarter and half year ended September 30, 2026, were approved following a limited review.

Financial highlights

• Q2 revenue from operations was ₹18,524.14 lakh, versus ₹18,588.27 lakh in Q2 FY26 and ₹19,381.04 lakh in Q1 FY27.

• Q2 PBT was ₹1,504.77 lakh versus ₹992.06 lakh YoY; H1 PBT was ₹3,197.58 lakh versus ₹2,087.37 lakh.

• Q2 PAT was ₹1,121.31 lakh versus ₹761.25 lakh YoY; H1 PAT was ₹2,263.80 lakh versus ₹1,591.37 lakh.

• H1 operating profit rose 26.23% to ₹78.11 Cr, with margin at 20.61% versus 16.62%; EBITDA increased 39.11% to ₹3,691.57 lakh.

• Q2 revenue declined 4.42% QoQ to ₹185.24 Cr; EBITDA fell 9.36% to ₹17.55 Cr and PAT fell 1.85% to ₹11.21 Cr.

Outlook and guidance

• 15–20% annual growth is targeted, supported by API volume expansion, regulated-market growth, process innovation and cost optimization.

• Plans include export diversification, compliance and capacity investment, and development of Bisoprolol Fumarate, Brivaracetam and Tegoprazan Fumarate.